INVESTIGATION OF THE ELIMINATION OF DABIGATRAN BY HAEMODIALYSIS IN PATIENTS WITH END STAGE RENAL DISEASE (ESRD)

被引：0
|
作者：
Haertter, S. [1 ]
Trenmmel, M. [1 ]
Nehmiz, G. [4 ]
Liesenfeld, K. [1 ]
Moschetti, V. [1 ]
Peters, H. [2 ]
Wagner, F. [3 ]
Formella, S. [5 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med, Ingelheim, Germany
[2] Charite, Dept Nephrol, Berlin, Germany
[3] Charite Res Org, Berlin, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] Effective Elimination of Dabigatran with Haemodialysis: A Phase I Single Centre Study in Patients with End-Stage Renal Disease
    Wagner, Frank
    Peters, Harm
    Formella, Stephan
    Wiegert, Erol
    Moschetti, Viktoria
    Khadzhynov, Dmytro
    Clemens, Andreas
    CIRCULATION, 2011, 124 (21)
  • [2] Effective elimination of dabigatran by haemodialysis A phase I single-centre study in patients with end-stage renal disease
    Khadzhynov, Dmytro
    Wagner, Frank
    Formella, Stephan
    Wiegert, Erol
    Moschetti, Viktoria
    Slowinski, Torsten
    Neumayer, Hans-H.
    Liesenfeld, Karl-Heinz
    Lehr, Thorsten
    Haertter, Sebastian
    Friedman, Jeffrey
    Peters, Harm
    Clemens, Andreas
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (04) : 596 - 605
  • [3] Blood Lead in End-Stage Renal Disease (ESRD) Patients who were on Maintainence Haemodialysis
    Palaneeswari, Subha M.
    Rajan, P. M. Abraham Sam
    Silambanan, Santhi
    Jothimalar
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2012, 6 (10) : 1633 - 1635
  • [4] Modelling and simulation of redistribution of dabigatran after elimination by hemodialysis in patients with end stage renal disease
    Liesenfeld, K-H
    Lehr, T.
    Moschetti, V
    Formella, S.
    Clemens, A.
    Staab, A.
    Haertter, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 597 - 598
  • [5] Smoking and hyperparathyroidism in patients with end stage renal disease (ESRD)
    Tripepi, Giovanni
    Pizzini, Patrizia
    Cutrupi, Sebastiano
    Mallamaci, Francesca
    Zoccali, Carmine
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 139 - 139
  • [6] HYPERMAGNESEMIA IN DIABETIC END STAGE RENAL DISEASE (ESRD) PATIENTS
    Shashidhar, K. N.
    Kunder, Mamatha
    Shenoy, K. Anitha
    Hemalatha, A.
    Kutty, A. V. M.
    Shetty, H. V.
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2007, 22 (02) : 164 - 164
  • [7] Hypermagnesemia in diabetic end stage renal disease (ESRD) patients
    K N Shashidhar
    Mamatha Kunder
    K Anitha Shenoy
    A Hemalatha
    AVM Kutty
    HV Shetty
    Indian Journal of Clinical Biochemistry, 2007, 22 (2) : 164 - 164
  • [8] End Stage Renal Disease (ESRD) in Patients with Rheumatoid Arthritis
    Paudyal, Sunita
    Bethel, Monique
    Yang, Frances
    Oliver, Alyce
    Skelton, Michael
    Rice, Christopher
    Le, Brian
    Brown, Shilpa
    Nahman, Stanley
    Carbone, Laura
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [9] Negative emotional states and coping strategies in patients with End Stage Renal Disease (ESRD) undergoing chronic haemodialysis
    Patil, Abhijeet Subhash
    Karkal, Ravichandra
    Chandran, Mohan
    Pai, Santosh
    INDIAN JOURNAL OF PSYCHIATRY, 2015, 57 (05) : S35 - S35
  • [10] Altered non-renal elimination in end stage renal disease (ESRD): The role of inflammation
    Reed, Jessica
    Williams, Pauline
    Schmith, Virginia
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 307 - 307
12345